Biosimilars Reviewed by Expert Panel

Save

As the number of biosimilars in development keeps on growing, reaching nearly 700 products to date, demand for data from randomized controlled trials (RCTs) and an understanding of these new biologics  is peaking the interest of many. 

The Week in Review - 4 March 2016

Save

Highlights from this week on RheumNow:

TNF Inhibition and Heart Failure

Save

Clinicians often face the issue of using a TNF inhibitor (TNFi) in patients with heart failure or cardiac disease. Here are the facts and data necessary to make a cogent decision to use or avoid TNFi.

Less Treatment, Responses and Safety in Elder-Onset Rheumatoid Arthritis

Save

A recent review compared elderly-onset rheumatoid arthritis (EORA) to those with younger-onset rheumatoid arthritis (YORA) to assess treatment responses and safety issues with biologics and DMARDS. EORA is generally defined as the onset of rheumatoid arthritis after age 60 years.

RA Flares Common After Anti-TNF Withdrawal

Save

The risk of a flare increased by more than three-fold over 1 year when patients with longstanding rheumatoid arthritis (RA) in remission, or with stable low disease activity, stopped their anti-tumor necrosis factor (TNF) treatment, Dutch researchers reported.

RWCS 2016 – Rheumatoid Review, Psoriatic Arthritis and Medical Marijuana

Save

The Rheumatology Winter Clinical Symposia launched its 9th annual conference yesterday in Maui. Highlights of this meeting will be covered by RheumNow from Wednesday 2/10 till Saturday 2/13.

Rheumatoid Arthritis Year in Review

Rheumatoid Modern Management is Better but More Costly

Save

The mantra of rheumatologists worldwide is to treat rheumatoid arthritis (RA) earlier and more aggressively. While referral of early RA patients has improved, there is little data demonstrating that more aggressive treatment works or is cost effective.

FDA Advisory Arthritis Committee Votes to Approve the CT-P13 (infliximab) Biosimilar

Save

On Tuesday February 9th Celltrion presented its biosimilar developmental data to the FDA as they sought approval for their CT-P13 (called Inflectra), a biosimilar of infliximab (Remicade).

FDA Reviews Celltrion's Remicade Biosimilar Today

Save

The arthritis advisory committee of the Food and Drug Administration (FDA) is scheduled to meet today, February 9th to review the efficacy and safety of Celltrion's biosimilar form of infliximab (Remicade) that is currently marketed in other countries.

Rheumatoid Arthritis, TNF inhibitors and the Risk of Skin Cancer

Save

Rheumatoid arthritis (RA) patients are said to have a neutral risk for neoplasia, but this is because they have a lower risk of colon cancer and breast cancer but a higher risk of lung cancer, lymphoma and skin cancers.

No Significant Increased Risk with TNF Inhibitors During Pregnancy

Save

A population-based study of 1,272,424 live-born infants from Denmark and Sweden examined the prevalence of birth defects among infants born to 683 women with chronic inflammatory disease (inflammatory bowel disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, or psoriasis)

Updated RA Treat-to-Target International Recommendations

Save

In 2010, Smolen and a group of international rheumatologists developed a series of recommendations addressing the concept of treat-to-target (T2T) in the management of rheumatoid arthritis (RA).

Biosimilar Reports - January 2016

Save

Biosimilars are the fastest developing product line within the pharmaceutical industry. There is unanimous worldwide interest in the continued use of biologics for immune mediated disorders.

Risk of Multiple Sclerosis with TNF Inhibitor Therapy

Save

Researchers from the DANBIO registry have linked their registry of 30,033 arthritis patients with the Danish Multiple Sclerosis Registry (DMSR) to identify all new multiple sclerosis cases occuring in arthritis patients and those receiving TNF inhibitors (TNFi). 

TNF Inhibitors May Increase Cardiac Risks in Elderly

Save

A retrospective study of elderly rheumatoid arthritis (RA) patients on Medicare was conducted by a group of researchers from the University of Alabama.

Game-Changers 2015: Refining Treatment in Arthritis

Save

Widening experience with JAK inhibition for rheumatoid arthritis (RA) and tapering medications among RA patients in remission, along with the success of secukinumab for psoriatic arthritis (PsA), were the most important advances in rheumatology in 2015, according to specialists responding toMedPa

Secukinumab Shows Efficacy in Two Ankylosing Spondylitis Trials

Save

NEJM has published the results of two studies wherein IL-17 inhibition with secukinumab (SEC) was shown to be effective in patients with anklylosing spondylitis.

2015 ACR RA Guidelines Released– Finally! (Best of 2015: #2)

Save

ACR 2015 RA treatment guidelines were published yesterday, nearly a year after they were preliminarily presented at the 2014 ACR meeting in Boston. After a year of review and revision these have been posted.

How I Choose Biologics (Best of 2015)

Save

Clinical decision-making, occurring at the intersection of the ’art’ and the ’science’ of medicine, remains enigmatic and controversial.

RA Guidelines, Methotrexate and Mortal Risks in Gout: November 2015 top social media news

Save

Here's what you may have missed: in November 2015, RheumNow published 80 tweets on news, research and teaching points that impact the rheumatology community. We had a reach (impressions) of 79,100, 79 mentions, and over 3399 visits to RheumNow.com to check out what we publish.